Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Capital Expenditures (2020 - 2025)

RxSight (RXST) has disclosed Capital Expenditures for 6 consecutive years, with $286000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 107.07% year-over-year to $286000.0, compared with a TTM value of $421000.0 through Dec 2025, down 22.75%, and an annual FY2025 reading of $421000.0, down 22.75% over the prior year.
  • Capital Expenditures was $286000.0 for Q4 2025 at RxSight, up from -$115000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.1 million in Q2 2024 and bottomed at -$4.0 million in Q4 2024.
  • Average Capital Expenditures over 5 years is $182050.0, with a median of $61000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures skyrocketed 1724.64% in 2022, then crashed 5801.41% in 2024.
  • Year by year, Capital Expenditures stood at -$138000.0 in 2021, then surged by 1724.64% to $2.2 million in 2022, then tumbled by 96.83% to $71000.0 in 2023, then plummeted by 5801.41% to -$4.0 million in 2024, then surged by 107.07% to $286000.0 in 2025.
  • Business Quant data shows Capital Expenditures for RXST at $286000.0 in Q4 2025, -$115000.0 in Q3 2025, and $46000.0 in Q2 2025.